BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 517 filers reported holding BIO-TECHNE CORP in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,225,132 | -17.1% | 120,833 | -0.6% | 0.03% | -11.1% |
| Q2 2023 | $9,925,820 | +16.7% | 121,595 | +6.0% | 0.04% | +5.9% |
| Q1 2023 | $8,506,712 | -10.2% | 114,661 | +0.3% | 0.03% | -17.1% |
| Q4 2022 | $9,473,854 | +17.6% | 114,308 | +303.0% | 0.04% | +10.8% |
| Q3 2022 | $8,056,000 | -29.5% | 28,365 | -14.0% | 0.04% | -27.5% |
| Q2 2022 | $11,433,000 | -28.8% | 32,981 | -11.1% | 0.05% | -8.9% |
| Q1 2022 | $16,067,000 | -15.2% | 37,102 | +1.3% | 0.06% | -5.1% |
| Q4 2021 | $18,954,000 | +2.5% | 36,637 | -4.0% | 0.06% | -6.3% |
| Q3 2021 | $18,498,000 | +7.1% | 38,173 | -0.5% | 0.06% | +5.0% |
| Q2 2021 | $17,275,000 | +12.5% | 38,367 | -4.6% | 0.06% | +3.4% |
| Q1 2021 | $15,352,000 | +9.9% | 40,196 | -8.6% | 0.06% | +13.7% |
| Q4 2020 | $13,967,000 | +37.1% | 43,984 | +7.0% | 0.05% | +18.6% |
| Q3 2020 | $10,184,000 | -17.9% | 41,109 | -12.5% | 0.04% | -27.1% |
| Q2 2020 | $12,409,000 | +40.1% | 46,990 | +0.6% | 0.06% | +7.3% |
| Q1 2020 | $8,855,000 | -14.3% | 46,699 | -0.8% | 0.06% | +3.8% |
| Q4 2019 | $10,336,000 | +10.6% | 47,087 | -1.4% | 0.05% | -1.9% |
| Q3 2019 | $9,346,000 | -6.9% | 47,764 | -0.8% | 0.05% | -5.3% |
| Q2 2019 | $10,037,000 | +0.4% | 48,142 | -4.4% | 0.06% | -6.6% |
| Q1 2019 | $9,993,000 | +42.7% | 50,332 | +4.0% | 0.06% | +19.6% |
| Q4 2018 | $7,002,000 | -27.0% | 48,385 | +3.0% | 0.05% | -13.6% |
| Q3 2018 | $9,587,000 | +39.0% | 46,968 | +0.8% | 0.06% | +25.5% |
| Q2 2018 | $6,897,000 | -1.3% | 46,618 | +0.8% | 0.05% | -4.1% |
| Q1 2018 | $6,986,000 | +14.7% | 46,253 | -1.6% | 0.05% | +19.5% |
| Q4 2017 | $6,092,000 | +11.7% | 47,028 | +4.2% | 0.04% | 0.0% |
| Q3 2017 | $5,456,000 | -0.8% | 45,128 | -3.6% | 0.04% | 0.0% |
| Q2 2017 | $5,500,000 | +19.7% | 46,808 | +3.8% | 0.04% | +10.8% |
| Q1 2017 | $4,593,000 | -0.7% | 45,112 | +0.3% | 0.04% | -9.8% |
| Q4 2016 | $4,626,000 | -4.5% | 44,987 | +1.7% | 0.04% | -4.7% |
| Q3 2016 | $4,844,000 | -1.0% | 44,237 | +1.9% | 0.04% | -6.5% |
| Q2 2016 | $4,895,000 | +11.3% | 43,407 | -6.7% | 0.05% | +12.2% |
| Q1 2016 | $4,397,000 | +4.8% | 46,526 | -0.2% | 0.04% | +5.1% |
| Q4 2015 | $4,196,000 | -3.3% | 46,628 | -0.6% | 0.04% | +2.6% |
| Q3 2015 | $4,338,000 | -96.5% | 46,928 | -96.3% | 0.04% | -79.7% |
| Q2 2015 | $125,277,000 | -2.0% | 1,272,239 | -0.2% | 0.19% | -5.1% |
| Q1 2015 | $127,824,000 | +9.0% | 1,274,548 | +0.4% | 0.20% | +3.7% |
| Q4 2014 | $117,258,000 | – | 1,269,034 | – | 0.19% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |